Endomag: a new procedure saves women with breast cancer from unnecessary surgical complications

CAMBRIDGE, England – (COMMERCIAL THREAD) – A new procedure could now spare breast cancer patients from invasive surgery on their lymphatic system. At the MD Anderson Cancer Center, doctors pioneered the targeted axillary dissection (TAD) technique, where a tiny magnetic seed is placed in the lymph nodes of patients known to contain cancer. After a cycle of neoadjuvant chemotherapy aimed at reducing or even eradicating their cancer, before surgery, this new technique allows surgeons to monitor the response of targeted lymph nodes to chemotherapy without the need for initial invasive surgery, such as a complete axillary dissection.

The magnetic seed, known as Magseed®, allows surgeons to precisely remove the marked lymph node before chemotherapy and remove it with minimal damage to healthy lymph node tissue.

Lymph nodes are a vital part of the system that helps the body fight infections, but are also the first structures that breast cancer can spread to. In 40 to 75% of women, chemotherapy before surgery can clear the cancerous nodes.1,2,3 However, until now, there was no way to confirm the effectiveness of chemotherapy without removing a large number of lymph nodes from the armpits.

“The standard surgical approach for patients with breast cancer that has spread to the lymph nodes has been axillary lymphadenectomy (ALND), which involves removing most of the lymph nodes from the armpit.” explains Dr. Abigail Caudle, MD, who pioneered the TAD technique at MD Anderson. “Unfortunately, this approach is associated with significant complications that can impact a patient’s quality of life, including swelling, pain and decreased range of motion. Some patients have an excellent response to chemotherapy and may not have lymph node disease. We believe that these patients may not benefit from having all of their lymph nodes removed, although studies addressing this issue are not yet available.

The challenge was to identify those patients who could benefit from less aggressive surgery. By specifically removing the exact lymph nodes that had confirmed cancer at the time of diagnosis, as well as the lymph nodes most likely to contain the disease, we can now accurately assess whether cancer remains in the lymph nodes and consider not not have further surgery if there is no evidence of cancer.

It is widely reported that up to 70% of women who have had multiple nodes removed during an ALND procedure will develop complications related to their treatment, such as life-changing lymphedema.4.5.6 Lymphedema is a condition in which damage to the lymphatic system causes lymph fluid to build up in the body following lymphadenectomy, causing permanent symptoms of severe swelling, altered sensation, pain, and limitations in range. movements.3. There are currently over 10 million people in the United States living with lymphedema,seven and for many patients, lymphedema is incurable.8

“There is a radical change underway in breast cancer treatment as patients are increasingly informed of the options available to prevent side effects of treatment. At the forefront of this list are the procedures and technologies that can prevent lymphedema – an incurable, debilitating, progressive, and disfiguring swelling disease that can occur when the lymphatic system is damaged during surgery, radiation therapy, or chemotherapy. Women who win their battle with breast cancer consistently report that lymphedema can be worse than their cancer. Their cancer was cured. Their lymphedema is forever. In this modern world, every woman deserves all the benefits of our knowledge to alleviate the onset of the chronic disease of lymphedema ”, explains William Repicci, President and CEO of LE&RN

The seed of magnesia® The marker, used by surgeons at MD Anderson, is the world’s most studied non-radioactive seed, with the technology available in more than 40 countries around the world. Results of a series of past and ongoing multinational studies 9.10 demonstrated the ease and accuracy of labeling positive lymph nodes with a Magseed® marker with 100% success in surgical recovery, eliminating the need for unnecessary node removal.

This pioneering surgery illustrates the importance of new technologies such as Magseed in advancing the treatment of breast cancer. said Eric Mayes, CEO of Endomag. “These technologies have already helped more than 200,000 patients worldwide access a better level of cancer care. We are committed to continually learning from physicians around the world and providing access to cutting-edge clinical applications that will make a difference for these patients for years to come.

+++ END +++

About Endomag

Endomag is a global medical technology company that believes everyone deserves a better standard of cancer care. Many world-class doctors and hospitals are using the company’s technologies to help women with breast cancer avoid surgery when it isn’t needed and achieve better results when it is. .

At the heart of the company’s product platform is the Sentimag® tracking system. The Sentimag® The system includes a probe that functions as a metal detector and, when placed near the surface of the skin, is used to detect the magnetic seed of Endomag (Magseed®) or a liquid tracer (Magtrace®), for tissue localization and sentinel node biopsy procedures.

To date, Sentimag has been used in more than 250,000 tissue locations in more than 45 countries and on the six continents that perform breast cancer surgery. Technology has enabled these patients, regardless of their hospital setting, to access more precise and less invasive breast cancer treatment. The company’s technologies are also largely supported by extensive clinical data, with more than 5,000 patients having benefited from Magseed® marker studies, making it the most widely studied non-radioactive seed technology in the world.

Endomag is headquartered in Cambridge, UK, and an office in Austin, Texas.

The references

1 Kuerer HM, et al. Incidence and impact of documented eradication of axillary lymph node metastases from breast cancer before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999 Jul; 230 (1): 72-8.

2 Hennessy BT, et al. Result after complete pathological eradication of axillary lymph node metastases of breast cancer proven cytologically after primary chemotherapy. J Clin Oncol. 2005 Dec 20; 23 (36): 9304-11.

3 Dominici LS, et al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy combined with trastuzumab for HER2-positive breast cancer. Cancer. June 15, 2010; 116 (12): 2884-9.

4 Kakuda JT, et al. Objective assessment of axillary morbidity in the treatment of breast cancer. Am sur. 1999 Oct; 65 (10): 995-8.

5 Lucy, et al. Surgical Complications Associated with Sentinel Lymph Node Dissection (SLND) and Axillary Lymph Node Dissection Compared to SLND Alone in American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007 Aug 20; 25 (24): 3657-63.

6 Blanchard, et al. Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. Arch surgery. 2003 138 (5): 482–488.

seven Cancer research in the UK. Living with Lymphedema After Treatment. Available at: https://www.cancerresearchuk.org/about-cancer/breast-cancer/living-with/lymphoedema-after-treatment Last consulted, August 2020.

8 Anbari. A, et al. Breast cancer-related lymphedema and quality of life: a qualitative analysis over years of survival. Chronic disease. 2019: 0 (0): 1-12.

9 Simons JM, et al. Prospective Localization Trial of Magnetic Seeds of Cut Nodes after Neoadjuvant Chemotherapy in Node Positive Breast Cancer. ASBrS 2021, Poster 581650.

ten Green wood H, et al. Feasibility of magnetic seeds for preoperative localization of axillary lymph nodes in the treatment of breast cancer. American Journal of Roentgenology. 2019; 213: 953-957.

Comments are closed.